XRCC3 and non-small cell lung carcinoma: Survival of advanced NSCLC and XRCC3 Thr241Met polymorphism was reported in 6 studies [11], [13]–[15], [30], but only 4 [11], [13]–[15] studies provided available data for meta-analysis.